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A randomized, controlled trial on the
effects of almonds on lipoprotein response
to a higher carbohydrate, lower fat diet in
men and women with abdominal adiposity
Paul T. Williams1†, Nathalie Bergeron1,2†, Sally Chiu1 and Ronald M. Krauss1*
Abstract
Background: Almonds have been shown to lower LDL cholesterol but there is limited information regarding their
effects on the dyslipidemia characterized by increased levels of very low density lipoproteins (VLDL) and small,
dense low-density lipoprotein (LDL) particles that is associated with abdominal adiposity and high carbohydrate
intake. The objective of the present study was to test whether substitution of almonds for other foods attenuates
carbohydrate-induced increases in small, dense LDL in individuals with increased abdominal adiposity.
Methods: This was a randomized cross-over study of three 3wk diets, separated by 2wk washouts: a higher-
carbohydrate (CHO) reference diet (CHOhigh), a higher-CHO diet with isocaloric substitution of 20% kcal (E) from
almonds (CHOhigh + almonds), and a lower-CHO reference diet (CHOlow) in 9 men and 15 women who were
overweight or obese. The two CHOhigh diets contained 50% carbohydrate, 15% protein, 35% fat (6% saturated, 21%
monounsaturated, 8% polyunsaturated), while the CHOlow diet contained 25% carbohydrate, 28% protein, 47% fat
(8% saturated, 28% monounsaturated, 8% polyunsaturated). Lipoprotein subfraction concentrations were measured
by ion mobility.
Results: Relative to the CHOlow diet: 1) the CHOhigh + almonds diet significantly increased small, dense LDLIIIa (mean
difference ± SE: 28.6 ± 10.4 nmol/L, P = 0.008), and reduced LDL-peak diameter (− 1.7 ± 0.6 Å, P = 0.008); 2) the
CHOhigh diet significantly increased medium-sized LDLIIb (24.8 ± 11.4 nmol/L, P = 0.04) and large VLDL (3.7 ± 1.8
nmol/L, P = 0.05). Relative to CHOlow, the effects of CHOhigh on LDLIIIa (17.7 ± 10.6 nmol/L) and LDL-peak diameter
(− 1.1 ± 0.6 Å) were consistent with those of CHOhigh + almonds, and the effects of CHOhigh + almonds on LDLIIb (21.0 ±
11.2 nmol/L) and large VLDL (2.8 ± 1.8 nmol/L) were consistent with those of CHOhigh, but did not achieve statistical
significance (P > 0.05). None of the variables examined showed a significant difference between the CHOhigh +
almonds and CHOhigh diets (P > 0.05).
Conclusion: Our analyses provided no evidence that deriving 20% E from almonds significantly modifies increases
in levels of small, dense LDL or other plasma lipoprotein changes induced by a higher carbohydrate low saturated
fat diet in individuals with increased abdominal adiposity.
Trial registration: Clinicaltrials.gov NCT01792648.
Keywords: Almonds, Triglycerides, Lipids, Lipoprotein size, High carbohydrate
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: rkrauss@chori.org
†Paul T. Williams and Nathalie Bergeron contributed equally to this work.
1Children’s Hospital Oakland Research Institute, Oakland, California, USA
Full list of author information is available at the end of the article
Williams et al. Lipids in Health and Disease           (2019) 18:83 
https://doi.org/10.1186/s12944-019-1025-4
Background
Almonds appear to promote healthy blood lipid and lipopro-
tein levels [1]. A recent meta-analysis of randomized con-
trolled clinical trials found that almond consumption
reduced plasma total cholesterol concentrations by 0.15
mmol/L , LDL-cholesterol concentrations by 0.12 mmol/L,
and triglyceride concentrations by 0.07 mmol/L [2]. More-
over, a meta-analysis of prospective epidemiologic studies re-
ported that increased consumption of almonds and other
nuts was associated with a substantial reduction in CVD
mortality (RR 0.73; 95% CI 0.68–0.78) for the highest vs low-
est quintile of intake [3].
Low density lipoproteins include multiple subclasses
that range from small, dense, lipid-depleted LDL parti-
cles to large, buoyant, cholesterol-enriched LDL particles
[4]. Small LDL particles have been shown to be more
strongly associated with increased CVD risk than larger
LDL [5–7]. High plasma concentrations of small LDL
particles and triglyceride, and low HDL-cholesterol con-
centrations define atherogenic dyslipidemia [8]. This
dyslipidemia is one component of metabolic syndrome,
which also includes abdominal obesity (defined by in-
creased waist circumference), and/or dysglycemia, and/
or high blood pressure.
The optimal dietary macronutrient distribution for im-
proving blood lipids and overall CVD risk may differ
across individuals. Replacement of dietary total and satu-
rated fat with carbohydrates effectively lowers total and
LDL-cholesterol [9]. However, we have shown that in
most healthy individuals, low fat, high carbohydrate diets
do not result in overall improvements in lipoprotein
profiles and can instead increase plasma triglycerides
and small, dense LDL particle concentration [10–12].
Analysis of combined data from several dietary interven-
tion studies, in which carbohydrate and fat intakes var-
ied inversely over a broad range and where protein
intake was constant, revealed a strong linear relationship
between increasing carbohydrate intake and the athero-
genic lipoprotein phenotype defined by high concentra-
tions of small dense LDL particles [9].
A triglyceride-lowering effect of almonds may be es-
pecially beneficial to the approximately one-third of
Americans with metabolic syndrome [13], particularly
if levels of small LDL are also reduced with almond
supplementation (triglycerides and small LDL being
concordantly related [8]). While increasing evidence
supports the cardiometabolic benefit of restricting
dietary carbohydrates in individuals with the athero-
genic dyslipidemia of metabolic syndrome, for those
unwilling to do so, we sought to test whether al-
mond consumption can reduce levels of small and
medium LDL particles without the need to restrict




The study was conducted between July 2012 and January
2016 at the Cholesterol Research Center (Berkeley, CA).
Twenty four men and women were recruited from par-
ticipants in our previous dietary studies and from the
local community through internet and newspaper adver-
tisements, outreach programs, bulk mailing and referrals
through collaborations with other academic or corporate
institutions. Participants who passed a self-administered
web-based pre-screening questionnaire were contacted
by a recruiter to review the eligibility requirements and
study protocol, and by the study nutritionist to discuss
the dietary requirements. Those who agreed to the study
protocol received a clinical assessment and blood draw
during their initial screening visit. This study was con-
ducted according to the guidelines laid down in the Dec-
laration of Helsinki and the procedures involving human
subjects were approved by the Children’s Hospital and
Research Center Oakland Institutional Review Board.
Written informed consent was obtained from all sub-
jects. This clinical trial was registered on ClinicalTrials.-
gov under the identifier NCT01792648 (https://
clinicaltrials.gov/ct2/show/NCT01792648).
Our initial intent was to study individuals with athero-
genic dyslipidemia of the metabolic syndrome, defined by
triglycerides ≥1.69 mmol/L, HDL-cholesterol < 1.03
mmol/L (men) or < 1.29 mmol/L (women), and with at
least one additional characteristic of metabolic syndrome
(waist circumference > 102 cm (men) or > 88 cm (women),
blood pressure ≥ 130/≥85mmHg, or fasting glucose ≥6.1
mmol/L) [14]. Of the screened participants who had tri-
glycerides > 1.69 mmol/L, only ~ 65% had low
HDL-cholesterol levels consistent with atherogenic dyslip-
idemia. Of these, less than 10% had one additional criter-
ion for metabolic syndrome and were willing to take part
in the study. Such low prevalence of atherogenic dyslipid-
emia with features of the metabolic syndrome may be a
consequence of our stringent enrollment criteria which
excluded individuals taking lipid- or glucose-lowering
medications, smokers, and the presence of comorbidities.
As such, and after sustained difficulty identifying partici-
pants who met these criteria, only abdominal obesity
(waist circumference > 88 cm for women and > 102 cm for
men) was retained as the selection criterion. Of the 24
participants who completed the study, 2 did not meet the
waist criterion but had other characteristics of metabolic
syndrome. Exclusion of these two participants from data
analysis did not affect any of the parameters measured
(lipids, lipoproteins, blood pressure, insulin, glucose, in-
flammatory markers). Changes to the enrollment criteria
were approved by our Institutional Review Board.
Additional screening inclusion criteria included: 1) ≥
20 years; 2) no history of coronary heart disease,
Williams et al. Lipids in Health and Disease           (2019) 18:83 Page 2 of 9
cerebrovascular disease, peripheral vascular disease,
bleeding disorder, liver or renal disease, diabetes, lung
disease, HIV, or cancer (other than skin cancer) in the
last 5 years; 3) not pregnant or breast feeding, and agree-
ing to use appropriate barrier contraception throughout
the study for women of childbearing potential; 4) no
current use of hormones or drugs known to affect lipid
metabolism or blood pressure; 5) no current use of nico-
tine products or recreational drugs; 6) willingness to ab-
stain from alcohol or dietary supplements during the
study; 7) systolic blood pressure < 160mmHg and dia-
stolic blood pressure < 95mmHg; 8) body mass index
(BMI) ≤ 38 kg/m2; 9) total- and LDL-cholesterol < 95th
percentile for sex and age, 10) fasting triglycerides > 0.56
mmol/L and < 5.65 mmol/L, 11) fasting blood sugar
< 7.0 mmol/L ; 12) thyroid stimulating hormone (TSH)
within normal range; and 13) weight stable for > 3
months.
Experimental design and setting of the study
The diet intervention was carried out on an outpatient
basis with careful monitoring of compliance. In a ran-
domized crossover design, each participant consumed
the three experimental diets (a higher-carbohydrate
(CHO) reference diet (CHOhigh); a higher-CHO diet with
almonds (CHOhigh + almonds); and a lower-CHO reference
diet (CHOlow)) for 3 weeks each, separated by 2-week
washout periods during which participants consumed
their habitual diet (see Additional file 1: Table S1). Diet
assignments were kept in sequentially numbered sealed
envelopes and assigned to the participant by the clinic
staff 1–2 days before starting the intervention. Investiga-
tors and laboratory staff were blinded to diet assignment,
while clinic staff were not. Participants were not informed
of their diet assignment, but due to the nature of the ex-
perimental diets, they were likely able to identify them.
The three experimental diets consisted of a higher carbo-
hydrate reference diet (CHOhigh diet: 50% E carbohydrate;
15% protein; 35% total fat); an almond-supplemented
(20% E) diet with similar macronutrient composition to
the higher carbohydrate reference diet (CHOhigh + almond
diet: 50% E carbohydrate; 15% protein; 35% total fat); and
a lower carbohydrate reference diet (CHOlow: 25% E
carbohydrate; 28% protein; 47% total fat). The CHOhigh
diet followed current dietary recommendations that focus
on restricting saturated fat and increasing intake of unsat-
urated fat (Table 1). The CHOhigh + almond diet provided
20% E from almonds in partial replacement for cooking
oils and other fat sources (avocados, olives, etc.), with all
other foods being otherwise comparable among the stand-
ard reference and almond-supplemented diets. Almonds
(nonpareil variety) were provided by the Almond Board of
California. They were distributed to participants in
pre-weighed packets when consumed as raw whole
unsalted almonds (10% E), with the remaining al-
monds (10% E) consumed as raw almond meal inte-
grated in customized unit foods (a choice of either
roasted pepper almond spread, almond soup or al-
mond cake). For both the CHOhigh and CHOhigh + al-
mond diets, the ratio of starch to total sugars was 60/
40, with fruit and dairy products constituting the
bulk of total sugars, and added sugars representing
6% of daily calories. The composition of the CHOlow
diet was based on our earlier findings that more ex-
treme carbohydrate restriction, from 54% E to 26%
E, is required to significantly reduce LDL-cholesterol
as well as small and very small LDL particles,
whereas more moderate carbohydrate restriction
(39% E) failed to significantly reduce LDL-cholesterol
or its component subclasses [15]. For the CHOlow
diet, the ratio of starch to total sugars was 70/30, with fruit
constituting the bulk of total sugars and added sugars
representing < 3% of daily calories. During the washout
period the participants consumed their usual home diets.
Comparable amounts of total fat in the standard reference
and almond-supplemented diets were achieved primarily
by limiting intake of foods rich in unsaturated fat and par-
tially replacing cooking oils with almonds.
Participants were provided ~ 65% daily energy in the
form of two frozen entrees (lunch and dinner) and
snacks. In addition, participants received detailed dietary
instructions, standardized menus, checklists, and shop-
ping lists for home preparation of breakfast and sides for
the remaining food items on the menu. Itemized grocery
receipts were collected regularly from participants to
verify their purchase of perishable foods on their shop-
ping list. Participants were instructed to eat all food
items provided/prescribed, and to report any deviations
from the protocol. A compliance score (1–5-point scale,
where 5 is indicative of high compliance) was assigned
to each study participant by the staff nutritionist, based
on menu checklists, itemized grocery receipts and infor-
mation gathered from weekly interactions.
Table 1 Composition of experimental dietsa
CHOhigh + almond CHOhigh CHOlow
Carbohydrate, % kcal 50 50 25
Protein, % kcal 15 15 28
Total fat, % kcal 35 35 47
SFA 6 6 8
MUFA 21 21 28
PUFA 8 8 8
Cholesterol (mg/d) 218 257 265
Fiber (g/d) 39 32 31
aCalculated values (Nutrition Data System for Research software 2010) for
2500 kcal 3-day menus. MUFA monounsaturated fatty acids, PUFA
polyunsaturated fatty acids
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The nutrient composition of the diets was assessed
using ProNutra software (Viocare Technologies, Inc.)
and the Nutrition Data System for Research (University
of Minnesota). Three-day rotating menus were provided
at four calorie levels (2000, 2500, 3000, 3500 kcal) for
each of the diets, and snacks (200–350 kcal) similar in
nutrient composition to the experimental diets were
provided for individuals whose calorie needs were inter-
mediate to the 4 calorie levels available. The participants’
energy requirements for maintaining stable weight were
estimated using the Institute of Medicine equation [16].
During the study, participants were required to maintain
their body weight within ±3% of their initial weight over
the course of any consecutive two weeks.
Height and weight were measured during the clinic
visits. Participants wore a pedometer to monitor daily
steps. Baseline steps per day were measured during the
study run-in period and participants were asked to
maintain this level of activity throughout the study.
Number of steps and other physical activities were re-
corded in logs and reviewed during weekly diet visits.
Fasting blood samples were collected at the end of each
dietary period for measurement of plasma lipids, lipo-
proteins, lipoprotein subfractions, and apolipoproteins B
and AI, as well as markers of insulin resistance and in-
flammation after fasting overnight for 12–14 h. Plasma
was separated immediately by centrifugation at 4 °C. In-
cluding the screening visit, participants visited the clinic
for a total of 7 blood draws and met with the research
nutritionist weekly on 14 separate occasions.
Laboratory measurements
Plasma triglycerides, total- and HDL-cholesterol were
measured by enzymatic endpoint analysis on a clin-
ical chemistry analyzer (Liasys 330) using method-
ology previously described [17–19]. Triglyceride and
cholesterol measurements are standardized through
the CDC-NHLBI lipid standardization program.
LDL-cholesterol was calculated from the Friedewald
equation [20]. ApoB and apoAI were determined by
immunoturbidimetric assay using the ITA reagent kit
[21, 22]. Plasma particle concentrations of VLDL,
intermediate density lipoprotein (IDL), LDL and
HDL subfractions were analyzed by gas-phase elec-
trophoresis (i.e., ion mobility [23, 24]). Inter-assay
variations of the subfraction measurements were
minimized by the inclusion of two in-house controls
in each preparatory process and by duplicate analysis
(CV < 15%).
Fasting glucose was measured by enzymatic endpoint
analysis and fasting insulin by ELISA (EZHI-14 K Hu-
man Insulin ELISA kit; Millipore, Billeria, MA, USA),
with two in-house quality control standards. HOMA-IR
was calculated as a marker of insulin resistance (insulin
(μU/mL) x glucose (mg/dL)/405) [25]. Plasma samples
were assayed for a multi-analyte panel of inflammatory
biomarkers (interleukins 1, 6, 8, and 10, resistin,
TNF-alpha, PAI-1, leptin, MCP, SAA, lipocalin, and
BAFF) using a multiplex immunoassay method through
a CLIA certified commercial laboratory (Rules Based
Medicine Austin, TX).
Statistical analyses
Randomization of the dietary sequence within random
size blocks was performed by the statistician assigned
to the study using a uniform random-number gener-
ator. Treatment, sequence, period and carryover ef-
fects were calculated using ANOVA for a cross-over
design with the statistical package Stata (version 11,
Austin, TX). The primary hypotheses were tested by
comparing the effects of the almond-supplemented
diet (20% E) with those of the two reference diets
that did not contain almond products: one with
similar content of carbohydrate, protein, and total,
saturated, monounsaturated, and polyunsaturated fat
(CHOhigh), and the other in which carbohydrate con-
tent was substantially reduced by substitution of pro-
tein and monounsaturated fat (CHOlow). The CHOhigh
diet was compared to the CHOlow diet to ensure that
the study design, interventions and duration of the
experimental diets and washout periods produced the
expected diet-induced changes. The primary hypoth-
esis was that almond supplementation would signifi-
cantly attenuate the increase in small, dense LDL and
apolipoprotein B relative to the CHOhigh standard ref-
erence diet while maintaining or enhancing the reduc-
tion in total cholesterol and LDL-cholesterol relative
to a CHOlow diet. Secondary hypotheses included the
effects of these dietary interventions on total:
HDL-cholesterol ratio, LDL peak particle size, triglyc-
erides, HDL measures (HDL-cholesterol, HDL sub-
classes, apoAI), and insulin resistance as estimated by
HOMA-IR, as well as a panel of inflammatory bio-
markers. The study was initially designed to detect a
5.3 mg/dL difference in LDL-cholesterol reduction
between the CHOhigh + almond diet and CHOhigh stand-
ard diet in 40 subjects. This detectable difference is
smaller than the expected 9.5 mg/dl reduction in
LDL-cholesterol for 20% E from almonds calculated
in the meta-analysis by Sabate et al. [26]. Interim
analyses determined midway through the study that
almond supplementation would be highly unlikely to
improve LDL-cholesterol levels by the study’s com-
pletion. Recruitment was therefore terminated at 24
subjects. Specifically, even if the remaining 16 sub-
jects all had LDL-cholesterol differences of 9.5 mg/
dL, we still would not have achieved the 5.3 mg/dL
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difference between diets which the study was de-
signed to detect.
Results
Figure 1 shows the details of participant recruitment and
enrollment. Table 2 presents the baseline characteristics
of the study participants. Fifteen participants (62.5%)
had total cholesterol ≥5.17 mmol/L, 17 (71%) had
LDL-cholesterol ≥2.59 mmol/L, 9 patients (37.5%) had
triglycerides ≥1.69 mmol/L, 7 patients (29.1%) had
HDL-cholesterol < 1.03 mmol/L if male and < 1.29
mmol/L if female, and all but 1 patient had at least one
screening lipid value outside the desirable range accord-
ing to the National Cholesterol Education Program-III
guidelines. One-third of the participants had fasting
plasma glucose > 6.1 mmol/L.
Participants were compliant with the dietary protocol,
with nutritionist-rated scores, on a scale of 1 to 5, aver-
aging 4.5 ± 0.9 (SD); 4.6 ± 0.8 and 4.4 ± 0.8, for the CHO-
high, CHOhigh + almond and CHOlow diets, respectively.
The overall significance levels for the effects of treat-
ment, period, sequence, and carryforward are presented
in Additional file 1: Table S2. Overall treatment effects
were significant for diastolic blood pressure (P = 0.01)
and medium-sized LDLIIb (P = 0.02). Period and carry-
forward effects were significant for diastolic blood pres-
sure (p = 0.02 for both), large LDLIIa (P = 0.03 and P =
0.02, respectively), and large LDLI (P = 0.05 and P = 0.02,
respectively). There were no significant sequence effects.
Table 3 presents the differences in the primary out-
come variables after completing each diet (the mean
levels after each diet are presented in Additional file 1:
Table S3). There were no significant weight changes on
any of the diets. There were no significant differences in
LDL-cholesterol or small to medium LDL subclasses be-
tween the CHOhigh + almonds diet and the CHOhigh diet
(the primary hypothesis). With 95% confidence, the
difference between the CHOhigh + almonds vs. CHOhigh diet
was between − 0.18 and 0.23 mmol/L for LDL-
cholesterol and between − 11.08 and 33.07 nmol/L for
LDL IIIa.
With respect to secondary hypotheses, relative to the
CHOlow diet: 1) the CHOhigh + almonds diet significantly
increased plasma concentrations of small, dense LDLIIIa
(mean difference ± SE: 28.6 ± 10.4 nmol/L, P = 0.008),
and reduced LDL-peak diameter (− 1.7 ± 0.6 Å, P =
0.008); and 2) the CHOhigh diet significantly increased
plasma concentrations of medium sized LDLIIb (24.8 ±
11.4 nmol/L, P = 0.04) and large VLDL (3.7 ± 1.8 nmol/L,
P = 0.05). While not achieving statistical significance, the
effects of CHOhigh on LDLIIIa (17.7 ± 10.6 nmol/L, P =
0.10) and LDL-peak diameter (− 1.1 ± 0.6 Å, P = 0.08)
were consistent with those of CHOhigh + almonds, and the
effects of CHOhigh + almond on LDLIIb (21.0 ± 11.2 nmol/
L, P = 0.07) and large VLDL (2.8 ± 1.8 nmol/L, P = 0.13)
were consistent with those of CHOhigh, when compared
to CHOlow. None of the lipoprotein variables showed
significant differences between the CHOhigh + almonds and
CHOhigh diets (p > 0.05). The results in Table 3 also
show no significant differences among the diets for
standard plasma lipid measurements, glucose, insulin,
HOMA-IR, apolipoproteins A1 and B, and HDL particle
concentrations.
The corresponding analyses for differences in interleu-
kin, resistin, tumor necrosis factor alpha (TNF-α), plas-
minogen activator inhibitor-1 (PAI-1), leptin, monocyte
chemotactic protein (MCP), serum amyloid A (SAA),




Did not meet inclusion criteria
n=35











Unable to adhere to diet, n=3
Unable to contact, n=1
Became pregnant, n=1
Fig. 1 Participant enrollment
Table 2 Screening characteristics of the study participants
Males (N = 9) Females (N = 15)
Mean SD Mean SD
Age, y 41 15 52 9
Body mass index (kg/m2) 31.7 4.2 31.0 3.3
Waist circumference (cm) 106.8 10.0 99.4 7.9
Systolic blood pressure (mmHg) 130 13 122 17
Diastolic blood pressure (mmHg) 75 8 71 10
Triglycerides (mmol/L) 1.76 0.34 1.39 0.68
Total cholesterol (mmol/L) 4.61 0.50 5.29 0.61
LDL-cholesterol (mmol/L) 2.79 0.43 2.92 0.60
HDL-cholesterol (mmol/L) 1.01 0.21 1.73 0.47
Total−/HDL-cholesterol 4.6 0.6 3.2 0.8
Glucose (mmol/L) 5.9 0.4 5.9 0.5
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hepatocyte growth factor (HGF) between diets are pre-
sented in Additional file 1: Tables S4-S6. Among these
inflammatory measures, only a borderline significant in-
crease in interleukin-1 was observed for the CHOhigh + al-
monds diet compared to the CHOlow diet (4.6 ± 2.3, P =
0.05).
Discussion
Numerous studies have shown significant lowering of
plasma and LDL-cholesterol levels when almonds are
substituted for carbohydrates in the diet, but little is
known of their metabolic effects in the context of higher
carbohydrate intake. In the present study we tested
whether lipoprotein measures of CVD risk are re-
duced by almond supplementation in the context of a
diet higher in carbohydrate, and with fat and protein
content that conform to current guidelines. Our ana-
lyses provided no evidence that modifying the stand-
ard reference diet (50% E carbohydrates, 15% protein,
35% total fat) with 20% E derived from almonds
Table 3 Mean differences in weight, blood pressure, lipoproteins and insulin resistance between diets
Mean and SE for differences between diets
CHOHigh + almonds-CHOHigh CHOHigh + almonds- CHOLow CHOHigh-CHOLow
Mean SE Mean SE Mean SE
Body mass (kg) −0.1 0.4 0.4 0.3 0.6 0.4
Body mass index (kg/m2) − 0.1 0.1 0.1 0.1 0.2 0.1
Waist circumference (cm) 0.4 0.6 0.7 0.6 0.3 0.6
Systolic BP (mmHg) −1 1 1 1 2 1
Diastolic BP (mmHg) −1 1 0 1 1 1
Triglycerides (mmol/L) 0.03 0.20 0.02 0.20 −0.02 0.20
Total cholesterol (mmol/L) −0.05 0.10 0.11 0.10 0.16 0.10
LDL-cholesterol (mmol/L) 0.02 0.10 0.04 0.10 0.02 0.10
HDL-cholesterol (mmol/L −0.08 0.06 −0.01 0.06 0.07 0.06
nonHDL-cholesterol (mmol/L) 0.02 0.12 0.11 0.11 0.09 0.11
Total−/HDL-cholesterol 0.0 0.1 0.1 0.1 0.0 0.1
Glucose (mmol/L) 0.1 0.1 −0.1 0.1 −0.1 0.1
Insulin (pmol/L) 1.6 1.7 0.6 1.7 −1.1 1.7
HOMA-IR 0.4 0.5 0.13 0.46 −0.30 0.46
Apolipoprotein AI (g/L) 0.01 0.02 0.03 0.02 0.03 0.02
Apolipoprotein B (g/L) −0.05 0.04 −0.01 0.04 0.04 0.04
HDL3&2a (nmol/L) 100 400 569 397 469 405
HDL2b (nmol/L) − 267 327 −18 316 249 323
LDL IVc (nmol/L) −0.6 2.6 2.5 2.6 2.5 2.6
LDL IVb (nmol/L) 3.9 5.2 7.7 5.0 3.8 5.1
LDL IVa (nmol/L) 8.7 10.6 14.0 10.3 5.3 10.3
LDL IIIb (nmol/L) 7.5 5.8 10.3 5.6 2.8 5.76
LDL IIIa (nmol/L) 11.0 10.7 28.6† 10.4 17.7 10.6
LDL IIb (nmol/L) −3.8 11.5 21.0 11.2 24.8* 11.4
LDL IIa (nmol/L) −7.0 11.2 0.2 10.8 7.2 11.1
LDL I (nmol/L) −1.8 16.4 −19.7 16.2 −19.7 15.2
IDL2 (nmol/L) 5.9 10.5 −5.8 10.1 −11.7 10.4
IDL1 (nmol/L) 4.2 7.3 11.3 7.0 7.0 7.2
Small VLDL (nmol/L) 1.4 3.3 3.3 3.2 1.9 3.2
Intermediate VLDL (nmol/L) −0.7 3.9 6.3 3.8 7.0 3.9
Large VLDL (nmol/L) −0.9 1.9 3.7 1.8 3.7* 1.8
LDL peak diameter (Å) −0.6 0.6 −1.7† 0.6 −1.1 0.6
* P ≤ 0.05; † P ≤ 0.01
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significantly lowers plasma LDL-cholesterol or total
cholesterol. Moreover, increases in small and midsize
LDL concentrations and reductions in LDL-peak
diameter were essentially the same for the higher
carbohydrate reference diet with or without the inclu-
sion of almond-derived products. Both renditions of
the higher carbohydrate diet increased LDLIIIa and
LDLIIb plasma concentrations and reduced LDL par-
ticle diameter relative to the lower-carbohydrate
higher-fat diet.
The present findings differ from that of a recent study
in 31 overweight and obese individuals in which diets
providing almonds (42.5 g/d) or almonds and dark choc-
olate (42.5 g/d almonds, plus 43 g/d dark chocolate and
18 g/d cocoa powder) reduced LDL-cholesterol, and low-
ered large LDL (almond diet) and small LDL (almond
plus dark chocolate diet) in comparison to an average
American diet [27]. Discrepancies with the present find-
ings may reflect differences in the comparator diet which
was low in saturated fat (8% E) and high in fiber (31 g/d)
in the present study, but high in saturated fat (13% E)
and low in fiber (23 g/d) in the study by Lee et al. [27].
These findings suggest that the high unsaturated fatty
acid profile of almonds may contribute, at least in part,
to their lipid-lowering effects.
Almonds have been found to promote healthy blood lipid
levels, manifest as reductions in total cholesterol,
LDL-cholesterol and triglycerides [2]. To date, their effects
on plasma lipoprotein concentrations have been investi-
gated in eighteen publications that encompass 27 almond
vs. control group comparisons, 17 from parallel trials and
10 from cross-over designs [2]. These included studies in
healthy subjects, subjects with high cholesterol, and in dia-
betic patients. Reductions in total- and LDL-cholesterol are
reported to be greatest for almond intake ≥45 g and in
studies of individuals with non-optimal baseline lipid levels
as defined by the National Cholesterol Education Program
Adult Treatment Panel III guidelines (total cholesterol
≥200mg/dl; LDL-cholesterol≥100mg/dl) [28]. In the
current study, all but one patient had at least one screening
lipid value outside the desirable range according to the Na-
tional Cholesterol Education Program-III guidelines. Never-
theless we cannot rule out an effect of almond
consumption in patients with metabolic syndrome who dis-
play a greater degree of atherogenic dyslipidemia.
Several of the studies that contributed to the above
meta-analyses of almonds and lipoproteins [2] included
significant weight loss, although they were not among
the studies showing the most significant decreases in
total cholesterol, LDL-cholesterol, or plasma triglyceride
concentrations. In the present study, the subjects were
closely monitored to maintain stable weight, which
could have diminished improvements in LDL and other
lipoproteins.
In accordance with the initial protocol, the study was
terminated early when interim analyses showed no indi-
cation that almond mitigated the increases in small LDL
and triglycerides on a high carbohydrate diet. The
3-week interventions were also shorter than other al-
mond feeding studies (≥4 weeks) [2]. Nevertheless, a
3-week intervention in 24 subjects was sufficient to pro-
duce the expected increases in medium- and small-sized
LDL particle concentrations associated with increased
carbohydrate intake (Table 3). Significant carry forward
effects for diastolic blood pressure, LDL-cholesterol,
total cholesterol/HDL-cholesterol, apo B, and larger
LDL (Supplemental Table 2) suggest that the design
could have benefitted from a longer than 2-week wash-
out period, although prior crossover studies had wash-
outs of 2 weeks or less.
Limitations of the study include the small sample size,
relatively short feeding duration, and significant carryfor-
ward effects which may have contributed to the nonsig-
nificant almond effect on the primary endpoints. In the
24 subjects who completed the study, we showed that
the LDL-cholesterol difference between the CHOhigh + al-
monds diet and CHOhigh diet without almonds was 0.02 ±
0.20 mmol/L (mean difference ± 95% confidence inter-
val) which excludes the 0.25 mmol/L average reduction
in LDL-cholesterol for 20% E from almonds reported by
Sabate et al. [26]. The LDL-cholesterol difference was
nonsignificant when adjusted for carryforward effect (P =
0. 38) and the carryforward effect did not prevent the ex-
pected increase in LDLIIb for the high vs. low fat diet.
Addition of the 24 participants studied here to the 837 in-
cluded in a meta-analysis of almond effects on plasma li-
poproteins [2] would be unlikely to alter the conclusion
that “consumption of nuts as part of a healthy diet should
be encouraged to help in the maintenance of healthy
blood lipid levels and to reduce the risk of heart disease”.
Conclusion
The absence of differences in plasma LDL-cholesterol
and small dense LDL (primary endpoints), and other li-
poproteins (secondary endpoints) with CHOhigh + almonds
vs. CHOhigh diets provides evidence that in men and
women with abdominal obesity, almond supplementa-
tion in amounts representing 20% E does not attenuate
features of atherogenic dyslipidemia induced by higher
carbohydrate feeding. Thus, consumption of almonds
should not be considered a means of improving this dys-
lipidemia in the setting of higher CHO intake.
Additional file
Additional file 1: Table S1. Habitual dietary intake of study participants.
Table S2. Statistical analyses of body weight, blood pressure,
lipoproteins, and insulin resistance during a crossover study in 24 men
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and women. Table S3. Mean weight, blood pressure, lipoproteins and
insulin resistance at the end of each diet. Table S4. Statistical analyses of
interleukin, resistin, tumor necrosis factor alpha (TNF-α), plasminogen
activator inhibitor-1 (PAI-1), leptin, monocyte chemotactic protein (MCP),
serum amyloid A (SAA), lipocalin, and B lymphocyte activating factor
(BAFF) during a crossover study in 24 men and women. Table S5. Mean
differences in interleukin, resistin, tumor necrosis factor alpha (TNF-α),
plasminogen activator inhibitor-1 (PAI-1), leptin, monocyte chemotactic
protein (MCP), serum amyloid A (SAA), lipocalin, and B lymphocyte acti-
vating factor (BAFF) between diets. Table S6. Mean interleukin, resistin,
tumor necrosis factor alpha (TNF-α), plasminogen activator inhibitor-1
(PAI-1), leptin, monocyte chemotactic protein (MCP), serum amyloid A
(SAA), lipocalin, and B lymphocyte activating factor (BAFF) at the end of
each diet. (PDF 377 kb)
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